Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist
MISSOULA, Montana, July 24, 2024 – Inimmune, a clinical stage biotech company focused on the development of novel immunotherapies, vaccines, and vaccine adjuvants announced today the dosing of the first patient in its Phase 1 single ascending dose study of INI-4001 in patients with advanced solid tumors. This is an open-label, multiple-ascending dose, two-part dose […]
Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization
Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization
SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems
MISSOULA, Montana, July 16, 2024 – SPI Pharma, Inc. a global leader in biopharmaceutical excipient and adjuvant systems, and Inimmune, Corp., a pioneering biotechnology company specializing in the discovery and development of innate immune modulators, announce an agreement in principle to create a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. […]
